Group items tagged

ADT therapy with abiraterone inhibits androgen production from both testicular and adrenal origins.  This study finds that a decrease in androgen production through ADT did not always equal a decrease in PSA, indicating other mechanisms of prostate cancer profession.

Good brief review of the evidence of the psa flare

PSA flare is associated with docetaxol chemotherapy in men undergoing treat for prostate cancer.

Brief read...will re-read, but IV vitamin C (albeit relatively low doses) correlate with decline in psa and alkP.

Six cups of green tea daily in those men with prostate cancer found to reduce PSA, NK-KappB, and oxidative stress.  These levels were followed in men before and after surgery.

no change in prostate cancer progression in man with prostate cancer on testosterone therapy.    Additionally, the PSA decreased.  The follow up was 2 years.  Two negatives: first, this was an observation study of one man, second,  was that analysis was via serum and I don't see that aromatase activity was monitored.  

This is only the abstract, but the this study (sizable) found that risk of prostate cancer in men on testosterone therapy is "equivalent to that expected in the general population".  They found no effect on PSA by testosterone therapy.  

Abstract presented finds that Testosterone IM undecanoate significantly reduced metabolic syndrome parameters in men.  This study looked at men with secondary hypogonadism and late onset.  The ages were from 15-72.  The full is not available as of this post.  The study only looked at serum T.  This limits the usefulness of this test.  According to this abstract, no evaluation of SHBG was performed.  Though not significant, PSA and prostate volume increased.

Estradiol increases PSA secretion.

curcumin supresses PSA.

study finds little benefit from third generation aromatase inhibitor in reducing PSA.

Curcumin inhibits PSA expression.

curcumin reduces the genetic expression of PSA from androgen dependent and androgen independent prostate cancer.

As these authors call it--late onset hypogonadism (what is with all these names), Testosterone therapy provides no increased risk of prostate cancer or elevated PSA when followed for 5 years.

Interesting: 1 year f/u of 75 men on Testosterone therapy and high grade prostate intraepithelial neoplasia had no increase in PSA.

Good brief discussion of membrane Androgen receptor and intracellular Androgen receptor as well as the effects of aromatase and ER alpha. The point is that dual actions can be on going in the elevation of PSA values. Rightly so, this short rebuttal points out that a high T/DHT and a high mAR/iAR results in apoptosis.

Retrospective study finds that 2 years of Testosterone and GH do not change metabolic biomarkers, PSA, or disease risk.  LDL and TC were in fact decreased in the study arm without statin therapy.

study looked at androgen deprivation therapy in non-metastatic prostate cancer.  This study found that the elimination of ADR post 5 years was associated with low recurrence.  Relapse of increased PSA was associated with increasing Testosterone off of ADR.  This study did not look at estrogens or androgen metabolites.  Too short sided in its design.

Study finds new difference in Testosterone benefits and/or side effects between men < 65 with low T and men > 65 with low T.

Study finds no increase in PSA , cancer progression, or recurrence during and 31 months follow up in men with low T with prostate cancer treated with brachytherapy.